Appraisal of a Leishmania major Strain Stably Expressing mCherry Fluorescent Protein for Both In Vitro and In Vivo Studies of Potential Drugs and Vaccine against Cutaneous Leishmaniasis

Abstract

Background Leishmania major cutaneous leishmaniasis is an infectious zoonotic disease. It is produced by a digenetic parasite, which resides in the phagolysosomal compartment of different mammalian macrophage populations. There is an urgent need to develop new therapies (drugs) against this neglected disease that hits developing countries. The main goal of this work is to establish an easier and cheaper tool of choice for real-time monitoring of the establishment and progression of this pathology either in BALB/c mice or in vitro assays. To validate this new technique we vaccinated mice with an attenuated Δhsp70-II strain of Leishmania to assess protection against this disease.MethodologyWe engineered a transgenic L. major strain expressing the mCherry red-fluorescent protein for real-time monitoring of the parasitic load. This is achieved via measurement of fluorescence emission, allowing a weekly record of the footpads over eight weeks after the inoculation of BALB/c mice.Results In vitro results show a linear correlation between the number of parasites and fluorescence emission over a range of four logs. The minimum number of parasites (amastigote isolated from lesion) detected by their fluorescent phenotype was 10,000. The effect of antileishmanial drugs against mCherry+L. major infecting peritoneal macrophages were evaluated by direct assay of fluorescence emission, with IC50 values of 0.12, 0.56 and 9.20 µM for amphotericin B, miltefosine and paromomycin, respectively. An experimental vaccination trial based on the protection conferred by an attenuated Δhsp70-II mutant of Leishmania was used to validate the suitability of this technique in vivo.ConclusionsA Leishmania major strain expressing mCherry red-fluorescent protein enables the monitoring of parasitic load via measurement of fluorescence emission. This approach allows a simpler, faster, non-invasive and cost-effective technique to assess the clinical progression of the infection after drug or vaccine therapy.

EGFP reporter protein: its immunogenicity in Leishmania-infected BALB/c mice

“…Although many of these techniques are useful for in vitro studies and have helped to describe many important features of microbial pathogens, they are intrinsically bound to some limitations such as parasites progression to undetectable sites must be considered (Lang et al 2005). Successful labeling of invasive microorganisms by fluorescence and bioluminescence reporter genes recently provided a precise tool for infectivity evaluation and disease detection at early stages (Calvo-Álvarez et al 2012). Fluorescence signals are discovered with minimal handling taking advantage of fluorescence microscopy and flow cytometry (Bolhassani et al 2011;Lang et al 2005).…”

Zinc(II)-Dipicolylamine Coordination Complexes as Targeting and Chemotherapeutic Agents for Leishmania major

“…A cutaneous leishmaniasis animal model was developed by inoculating cohorts of female BALB/c mice with stationary mCherry-L. major (10 8 ) in the left hind footpad (39). Lesion progression was monitored by imaging the red fluorescence emission of the mCherry-L. major amastigotes and also by measuring the thickness of inflamed footpads with a Vernier caliper.…”

Trypanosomatids see the light: recent advances in bioimaging research

“…Drug Discovery Today Volume 20, Number 1 January 2015 [51,52] and perspectives for amphotericin B, paromomycin, and miltefosine, which are three drugs currently in clinical use against leishmaniasis [18]. Robust HTS systems have to mimic those natural conditions found by the parasites within the host cells.…”